Cardiogreen; Foxgreen; Cardio-Green; Fox Green; IC Green
|Molar mass||774.96 g/mol|
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
|what is: / ?)(|
Indocyanine green (ICG) is a cyanine dye used in medical diagnostics. It is used for determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography. It has a peak spectral absorption at about 800 nm. These infrared frequencies penetrate retinal layers, allowing ICG angiography to image deeper patterns of circulation than fluorescein angiography. ICG binds tightly to plasma proteins and becomes confined to the vascular system. ICG has a half-life of 150 to 180 seconds and is removed from circulation exclusively by the liver to bile juice.
ICG is a fluorescent dye which is used in medicine as an indicator substance (e.g. for photometric hepatic function diagnostics and fluorescence angiography) in cardiac, circulatory, hepatic and ophthalmic conditions. It is administered intravenously and, depending on liver performance, is eliminated from the body with a half life of approx. 3–4 minutes. ICG sodium salt is normally available in powder form and can be dissolved in various solvents; 5% (<5% depending on batch) sodium iodide is usually added to ensure better solubility. The sterile lyophilisate of a water-ICG solution is approved many European countries and the United States under the names ICG-Pulsion and IC-Green as a diagnostic for intravenous use.
- 1 History
- 2 Optical properties
- 3 Toxicity and side-effects
- 4 Uses
- 4.1 Angiography in ophthalmology.
- 4.2 Diagnostics for the non-invasive monitoring of liver or splanchnic perfusion
- 4.3 Perfusion diagnostics of tissues and organs
- 4.4 ICG-supported navigation for sentinel lymph node biopsy with tumors
- 4.5 Diagnosis of rheumatic diseases
- 4.6 Selectively over-heating cells (especially cancer)
- 5 References
- 6 External links
ICG was developed in the Second World War as a dye in photography and tested in 1957 at the Mayo Clinic for use in human medicine. After being granted FDA approval in 1959, ICG was initially used primarily in hepatic function diagnostics and later in cardiology. In 1964, S. Schilling was able to determine renal blood flow using ICG. From 1969, ICG was also used in the research and diagnosis of subretinal processes in the eye (in the choroid). In the years since 1980, the development of new types of cameras and better film material or new photometric measuring devices has cleared away many technical difficulties. In the mean time, the use of ICG in medicine (and especially in fluorescent angiography in ophthalmology) has become established as standard. A distinction is therefore also made, when describing fluorescent angiography, between NA fluorescent angiography and ICGA / ICG fluorescent angiography. Around 3,000 scientific papers on ICG have now been published worldwide.
The absorption and fluorescence spectrum of ICG is in the near infrared region. Both depend largely on the solvent used and the concentration. ICG absorbs mainly between 600 nm and 900 nm and emits fluorescence between 750 nm and 950 nm. The large overlapping of the absorption and fluorescence spectra leads to a marked reabsorption of the fluorescence by ICG itself. The fluorescence spectrum is very wide. Its maximum values are approx. 810 nm in water and approx. 830 nm in blood. For medical applications based on absorption, the maximum absorption at approx. 800 nm (in blood plasma at low concentrations) is important. In combination with fluorescence detection, lasers with a wavelength of around 780 nm are used. At this wavelength, it is still possible to detect the fluorescence of ICG by filtering out scattered light from the excitation beam.
Toxicity and side-effects
ICG is metabolized microsomally in the liver and only excreted via the liver and bile ducts; since it is not absorbed by the intestinal mucous membrane, the toxicity can be classified as low. Administration is not without risks during pregnancy. It has been known since September 2007 that ICG decomposes into toxic waste materials under the influence of UV light, creating a number of still unknown substances. A study published in February 2008, however, shows that ICG (the substance without UV effect) is basically, as such, of only minor toxicity. The intravenous LD50 values measured in animals are 60 mg/kg in mice and 87 mg/kg in rats. Occasionally – in one out of 42,000 cases – slight side-effects occur in humans such as sore throats and hot flushes. Effects such as anaphylactic shock, hypotension, tachycardia, dyspnea and urticaria only occurred in individual cases; the risk of severe side-effects rises in patients with chronic kidney impairment. The frequencies of mild, moderate and severe side-effects were only 0.15%, 0.2% and 0.05%; the rate of deaths is 1:333,333. For the competitor substance fluorescein, the proportion of people with side-effects is 4.8% and the death rate is 1:222,222.
Angiography in ophthalmology.
Because the preparation contains sodium iodide, a test must be carried out for iodine intolerance. Because around 5% of iodide is added, the iodine content of a 25 mg ampoule is 0.93 mg. In comparison, preparations for a bone marrow CT (140 ml) contain 300 mg/ml and for a corona angiography (200 ml) 350 mg/ml of iodine. ICG has the ability to bind 98% to plasma proteins – 80% to globulins and 20% to alpha-lipoprotein and albumin – and thus, in comparison with fluorescein as a marker, has a lower leakage (slower emergence of dye from the vessels, extravasally). Because of the plasma protein binding, ICG stays for up to 20–30 minutes in the vessels (intravasally). When the eye is examined, it thus stays for a long time in tissues with a higher blood flow, such as the choroid and the blood vessels of the retina. In ophthalmology, the ICG angiography is used for an angiography of the ocular fundus in the following cases:
- If there is a suspicion of retinal damage with poorly defined edges and if there is bleeding
- In basic diagnostics, if there is a suspicion of a particular form of AMD
- If there is a suspicion of choroidal neovascularisation (CNV)
- If there is a suspicion of polypoidal choroidal vasculopathy (PCV)
- If there is a suspicion of retinal angiomatous proliferation (RAP)
- If there is a suspicion of choroidal melanoma
- If there is a suspicion of choroidal hemangioma
- If there is a suspicion of choroidal metastases
- In individual cases for extended diagnostics or documentation (differential diagnostics)
Diagnostics for the non-invasive monitoring of liver or splanchnic perfusion
Because of the high binding rate of ICG to plasma proteins, the substance allows liver / splanchnic perfusion to be measured by monitoring the changes in the ICG plasma disappearance rate (ICG-PDR). This method is therefore suitable as a parameter for predicting the probability of survival of intensive-care surgical patients. Since reduced PDR values can be measured in about two thirds of intensive-care surgical patients in whom expanded haemodynamic monitoring is indicated, it is clear that there is a significantly increased mortality rate here. Regular monitoring of the ICG-PDR (generally twice a day) helps to reveal restrictions in liver / splanchnic perfusion at an early stage. After intravenous ICG administration, the plasma disappearance rate is measured using an external monitoring device.the role of ICG for detection of liver reserve before liver resection in management of HCC.
Perfusion diagnostics of tissues and organs
ICG is used as a marker in the assessment of the perfusion of tissues and organs in many areas of medicine. The light needed for the excitation of the fluorescence is generated by a near infrared light source which is attached directly to a camera. A digital video camera allows the absorption of the ICG fluorescence to be recorded in real time, which means that perfusion can be assessed and documented. This is used in the following cases:
- Plastic surgery: skin and muscle transplants; determination of amputation level
- Abdominal surgery: gastrointestinal anastomosis
- General surgery: wound healing and ulcers
- Internal medicine: diabetic extremities
- Heart surgery: aortocoronary bypasses
In addition, ICG can also be used as a tracer in cerebral perfusion diagnostics. In the case of stroke patients, monitoring in the recovery phase seems to be achievable by measurement of both the ICG absorption and the fluorescence in everyday clinical conditions.
Sentinel lymph node biopsy (SLB or SLN biopsy) allows selective, minimally invasive access for assessment of the regional lymph node status with malignant tumours. The first draining lymph note, the "sentinel", represents an existing or non-existing tumour of an entire lymph node region. The method has been validated using radionuclides and/or blue dye for breast cancer, malignant melanoma and also gastrointestinal tumours and gives a good detection rate and sensitivity. For the SLB, a reduced mortality has been observed in comparison with complete lymph node dissection, but the methods have disadvantages with regard to availability, application and disposal of the radionuclide and the risk of anaphylaxis (up to 1%) for the blue dye. ICG, because of its near-infrared fluorescence and previous toxicity investigations, was evaluated in this investigation as a new, alternative method for SLB with regard to the clinical application of the transcutaneous navigation and lymph vessel visualisation and SLN detection. This technique is sometimes referred as fluorescence image-guided surgery (FIGS). ICG fluorescence navigation achieves high rates of detection and sensitivity in comparison with the conventional methods. Taking into account the learning curve required, the new, alternative method offers a combination of lymphography and SLB and the possibility of carrying out an SLB without the need for radioactive substances for solitary tumours
Diagnosis of rheumatic diseases
The Physikalisch-Technische Bundesanstalt and mivenion GmbH developed an imaging process, known as "Rheumascan", for the diagnosis of microcirculatory problems in the hands. This imaging process can be used with arthritic and rheumatoid diseases. ICG is used as the marker for the microcirculatory disorder. Rheumascan was presented for the first time in 2009 at the European Congress of Radiology.
Research in the area of ICG has by no means been completed at the current time. In particular, it seems that, under certain circumstances, such as the right laser strength and particular wavelengths, ICG may have the capacity to trigger a photodynamic reaction. ICG could thus also be used in the medium term as a PDT therapy. On the other hand, ICG can be used very universally in the area of (perfusion) diagnostics, and further research is therefore also being carried out here.
Selectively over-heating cells (especially cancer)
ICG absorbs near infra-red, especially light with a wavelength of about 805 nanometers. A laser of that wavelength can penetrate tissue. That means, dying tissue with injected ICG allows an 800 nm-810 nm laser to heat or overheat the dyed tissue without harming the surrounding tissue. Although overheating is the main mechanism for it to kill cells, a small amount of the laser energy absorbed by the ICG releases free radicals such as singlet oxygen that also damage target cells.
That works particularly well on cancer tumors, because tumors naturally absorb more ICG than other tissue. When ICG is injected near tumors, tumors react to the laser 2.5 times as much as the surrounding tissue does. It's also possible to target specific cells by conjugating the ICG to antibodies such as daclizumab (Dac), trastuzumab (Tra), or panitumumab (Pan).
Studies have been done, and are currently being done, on using this method to destroy cancer tumors without surgery. Early experiments on mice managed to slow tumor growth with a single laser treatment, but the tumor later recurred and metastasized. Other studies also showed a huge reduction in mouse tumor growth.
A study is being done on combining ICG laser therapy with something to trigger an immune response to the destroyed tumor, so your body's immune system will target any future appearance of that cancer (like a cancer vaccine). Glycated Chitosan is being trialed for that.
ICG and laser therapy has been shown to kill human pancreatic cancer cells (MIA PaCa-2, PANC-1, and BxPC-3) in vitro.
And they have been used to specifically target and kill P. gingivalis 381 and A. actinomycetemcomitans 67 bacterial infections in the jaw.
- Cardiogreen at Sigma-Aldrich
- Definition of indocyanine green, National Cancer Institute
- Optical Absorption of Indocyanine Green (ICG), Oregon Medical Laser Center
- Ophthalmic Diagnostic Photography; Indocyanine Green (ICG) Angiography University of Iowa Health Care
- "Indocyanine green solution". NIH. National Cancer Institute. Retrieved 1 December 2012.
- Wipper, Sabine Helena (2006). Validierung der Fluoreszenzangiographie zur intraoperativen Beurteilung und Quantifizierung der Myokardperfusion [Validation of fluorescence angiography for intraoperative assessment and quantification of myocardial perfusion] (Dissertation) (in German). LMU München: Faculty of Medicine. pp. 18–23. OCLC 723710136.
- Augustin, A.J., Krieglstein, G.K.,: Augenheilkunde, 2001, Springer-Verlag, ISBN 3-540-65947-1[page needed]
- Jarmo T. Alander, Ilkka Kaartinen, Aki Laakso, Tommi Pätilä, Thomas Spillmann, Valery V. Tuchin, Maarit Venermo, and Petri Välisuo, A Review of Indocyanine Green Fluorescent Imaging in Surgery, International Journal of Biomedical Imaging, Volume 2012 (2012), Article ID 940585. http://dx.doi.org/10.1155/2012/940585
- Optical Optical Properties of ICG (English)[page needed]
- Laperche, Yannick; Oudea, Marie-Claire; Lostanlen, Danielle (1977). "Toxic effects of indocyanine green on rat liver mitochondria". Toxicology and Applied Pharmacology 41 (2): 377–87. doi:10.1016/0041-008X(77)90039-4. PMID 19859.
- Cardiogreen at Sigma-Aldrich[page needed]
- Ophthalmic Diagnostic Photography; Indocyanine Green (ICG) Angiography University of Iowa Health Care[page needed]
- Steinkellner, Oliver; Gruber, Clemens; Wabnitz, Heidrun; Jelzow, Alexander; Steinbrink, Jens; Fiebach, Jochen B.; Macdonald, Rainer; Obrig, Hellmuth (1 January 2010). "Optical bedside monitoring of cerebral perfusion: technological and methodological advances applied in a study on acute ischemic stroke". Journal of Biomedical Optics 15 (6): 061708. doi:10.1117/1.3505009. PMID 21198156.
- Milej, Daniel; Gerega, Anna; Żołek, Norbert; Weigl, Wojciech; Kacprzak, Michał; Sawosz, Piotr; Mączewska, Joanna; Fronczewska, Katarzyna; Mayzner-Zawadzka, Ewa; Królicki, Leszek; Maniewski, Roman; Liebert, Adam (21 October 2012). "Time-resolved detection of fluorescent light during inflow of ICG to the brain—a methodological study". Physics in Medicine and Biology 57 (20): 6725–6742. doi:10.1088/0031-9155/57/20/6725. PMID 23032301.
- Weigl, W.; Milej, D.; Gerega, A.; Toczylowska, B.; Kacprzak, M.; Sawosz, P.; Botwicz, M.; Maniewski, R.; Mayzner-Zawadzka, E.; Liebert, A. (30 June 2013). "Assessment of cerebral perfusion in post-traumatic brain injury patients with the use of ICG-bolus tracking method". NeuroImage 85: 555–65. doi:10.1016/j.neuroimage.2013.06.065. PMID 23831529.
- Hirche, C.; Hünerbein, M. "Forschungsgruppe 'Fluoreszenzfarbstoff-gestützte Navigation zur Sentinel-Lymphknoten-Biopsie und real-time Lymphographie bei solitären Tumoren'" [Research Group 'fluorescent dye-based navigation for sentinel lymph node biopsy and real-time lymphography with solitary tumors'] (in German). Berufsgenossenschaftliche Unfallklinik Ludwigshafen (BG Klinik).
- Hirche, Christoph; Murawa, Dawid; Mohr, Zarah; Kneif, Soeren; Hünerbein, Michael (2010). "ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer". Breast Cancer Research and Treatment 121 (2): 373–8. doi:10.1007/s10549-010-0760-z. PMID 20140704.
- Hirche, C.; Dresel, S.; Krempien, R.; Hünerbein, M. (2010). "Sentinel Node Biopsy by Indocyanine Green Retention Fluorescence Detection for Inguinal Lymph Node Staging of Anal Cancer: Preliminary Experience". Annals of Surgical Oncology 17 (9): 2357–62. doi:10.1245/s10434-010-1010-7. PMID 20217256.
- Shafirstein, Gal; Bäumler, Wolfgang; Hennings, Leah J.; Siegel, Eric R.; Friedman, Ran; Moreno, Mauricio A.; Webber, Jessica; Jackson, Cassie; Griffin, Robert J. (2012). "Indocyanine green enhanced near-infrared laser treatment of murine mammary carcinoma". International Journal of Cancer 130 (5): 1208–15. doi:10.1002/ijc.26126. PMC 3190070. PMID 21484791.
- Chen, Wei R.; Adams, Robert L.; Heaton, Sean; Dickey, D.Thomas; Bartels, Kenneth E.; Nordquist, Robert E. (1995). "Chromophore-enhanced laser-tumor tissue photothermal interaction using an 808-nm diode laser". Cancer Letters 88 (1): 15–9. doi:10.1016/0304-3835(94)03609-M. PMID 7850768.
- Chen, Wei R.; Adams, Robert L.; Higgins, Aaron K.; Bartels, Kenneth E.; Nordquist, Robert E. (1996). "Photothermal effects on murine mammary tumors using indocyanine green and an 808-nm diode laser: An in vivo efficacy study". Cancer Letters 98 (2): 169–73. doi:10.1016/S0304-3835(06)80028-5. PMID 8556705.
- Li, Xingde; Beauvoit, Bertrand; White, Renita; Nioka, Shoko; Chance, Britton; Yodh, Arjun G. (1995). Chance, Britton; Alfano, Robert R, eds. "Tumor localization using fluorescence of indocyanine green (ICG) in rat models". Proc. SPIE Vol. 2389. Optical Tomography, Photon Migration, and Spectroscopy of Tissue and Model Media: Theory, Human Studies, and Instrumentation 2389: 789–97. Bibcode:1995SPIE.2389..789L. doi:10.1117/12.210021.
- Ogawa, Mikako; Kosaka, Nobuyuki; Choyke, Peter L.; Kobayashi, Hisataka (2009). "In vivo Molecular Imaging of Cancer with a Quenching Near-Infrared Fluorescent Probe Using Conjugates of Monoclonal Antibodies and Indocyanine Green". Cancer Research 69 (4): 1268–72. doi:10.1158/0008-5472.CAN-08-3116. PMC 2788996. PMID 19176373.
- Bromwell, Logan (November 2012). "Innovative Laser Therapy Offers New Hope for Breast Cancer Patients". Life Extension.
- Tseng, William W.; Saxton, Romaine E.; Deganutti, Adriana; Liu, Carson D. (2003). "Infrared Laser Activation of Indocyanine Green Inhibits Growth in Human Pancreatic Cancer". Pancreas 27 (3): e42–5. doi:10.1097/00006676-200310000-00018. PMID 14508139.
- Genina, Elina A.; Bashkatov, Alexey N.; Simonenko, Georgy V.; Tuchin, Valery V.; Yaroslavsky, Ilya V.; Altshuler, Gregory B. (2005). "Indocyanine green-laser thermolysis of acne vulgaris". In Van Den Bergh, Hubert; Vogel, Alfred. Therapeutic Laser Applications and Laser-Tissue Interactions II 5863. pp. 74–80. Bibcode:2005SPIE.5863...74G. doi:10.1117/12.633088.
- Genina, Elina A.; Bashkatov, Alexey N.; Simonenko, Georgy V.; Odoevskaya, Olga D.; Tuchin, Valery V.; Altshuler, Gregory B. (2004). "Low-intensity indocyanine-green laser phototherapy of acne vulgaris: Pilot study". Journal of Biomedical Optics 9 (4): 828–34. Bibcode:2004JBO.....9..828G. doi:10.1117/1.1756596. PMID 15250771.
- Boehm, TK; Ciancio, SG (2011). "Diode laser activated indocyanine green selectively kills bacteria". Journal of the International Academy of Periodontology 13 (2): 58–63. PMID 21913603.
- Stanga, Paulo E.; Lim, Jennifer I.; Hamilton, Peter (2003). "Indocyanine green angiography in chorioretinal diseases: Indications and interpretation: An evidence-based update". Ophthalmology 110 (1): 15–21; quiz 22–3. doi:10.1016/S0161-6420(02)01563-4. PMID 12511340.
- Optical Absorption of Indocyanine Green (ICG